Polyunsaturated fatty acids in vegetable (n-6) and marine (n-3) oils have been shown to reduce cholesterol levels in normolipidemic individuals. However, there is relatively little information available on the lipoprotein responses to dietary n-6 and n-3 fatty acids in individuals with genetic forms of hyperlipidemia at risk for premature cardiovascular disease. We studied five subjects with heterozygous familial hypercholesterolemia (FH), as well as five normal controls, on three rigidly controlled diets differing primarily in their fatty acid composition. FH subjects reduced their total plasma cholesterol by 34% during the n-3 diet and by 26% with the n-6 diet (both p<0.001) when compared with values while on a butter diet In addition, low density lipoprotein (LDL) cholesterol fell 31% and 29% (both/><0.001), and apolipoprotein B (apo B) levels dropped 28% and 27% (both p<0.01) during the n-3 and n-6 diets, respectively. A significant reduction of total and LDL cholesterol as well as of apo B was also noted in normal controls during n-3 and n-6 diets. Total plasma triglyceride and high density lipoprotein cholesterol fell significantly during n-3 diets in normal and FH subjects. Thus, FH and normal subjects respond in a similar fashion to diets low in saturated fatty acids and rich in n-3 and n-6, with decreased LDL cholesterol and apo B concentrations. (Arteriosclerosis and Thrombosis 1991;ll:47-54)
Effects of n-3 and n-6 Fatty Acid-Enriched Diets on Plasma Lipoproteins and Apolipoproteins in Heterozygous Familial Hypercholesterolemia
Karen E. Friday, R. Alan Failor, Marian T. Childs, and Edwin L. Bierman
Polyunsaturated fatty acids in vegetable (n-6) and marine (n-3) oils have been shown to reduce cholesterol levels in normolipidemic individuals. However, there is relatively little information available on the lipoprotein responses to dietary n-6 and n-3 fatty acids in individuals with genetic forms of hyperlipidemia at risk for premature cardiovascular disease. We studied five subjects with heterozygous familial hypercholesterolemia (FH), as well as five normal controls, on three rigidly controlled diets differing primarily in their fatty acid composition. FH subjects reduced their total plasma cholesterol by 34% during the n-3 diet and by 26% with the n-6 diet (both p<0.001) when compared with values while on a butter diet In addition, low density lipoprotein (LDL) cholesterol fell 31% and 29% (both/><0.001), and apolipoprotein B (apo B) levels dropped 28% and 27% (both p<0.01) during the n-3 and n-6 diets, respectively. A significant reduction of total and LDL cholesterol as well as of apo B was also noted in normal controls during n-3 and n-6 diets. Total plasma triglyceride and high density lipoprotein cholesterol fell significantly during n-3 diets in normal and FH subjects. Thus, FH and normal subjects respond in a similar fashion to diets low in saturated fatty acids and rich in n-3 and n-6, with decreased LDL cholesterol and apo B concentrations. (Arteriosclerosis and Thrombosis 1991;ll:47-54) P olyunsaturated fatty acids in oils of vegetable origin (mainly n-6 fatty acids) have long been known to have plasma cholesterol-lowering effects. 1 - 3 More recently, polyunsaturated fatty acids derived from marine oils (mainly n-3 fatty acids) have been the subject of much interest due to their lipid-lowering effects in normal and some hyperlipidemic subjects and their potential role in ameliorating atherosclerotic risk.
1 -
Epidemiological studies indicate that populations consuming large amounts of n-3 fatty acids 6 have relatively low incidences of atherosclerotic cardiovascular disease. 7 -9 While several potential mechanisms exist by which n-3 fatty acids inhibit the development of cardiovascular disease, 10 their effects on lipoprotein metabolism may play a significant role.
Dietary n-3 fatty acids have been shown to lower plasma lipoprotein levels when given to normal and to some but not all hyperlipidemic subjects. 511 " 14 The major metabolic effects of n-3 fatty acids appear to be reductions in the hepatic synthesis and plasma levels of triglyceride and very low density lipoprotein (VLDL) cholesterol. 12 Smaller decreases in low density lipoprotein (LDL) cholesterol levels have been demonstrated in normal subjects, while variable LDL changes have been noted in hyperlipidemic subjects.
'
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- 13 In previous studies, we 14 have shown a paradoxical increase in LDL cholesterol in three of four subjects with familial combined hyperlipidemia (FCHL) consuming an n-3-enriched diet.
In contrast to FCHL, a disorder characterized by multiple lipid phenotypes and increased apolipoprotein (apo) B synthesis, 15 
"
17 familial hypercholesterolemia (FH) is a metabolic disorder with impaired LDL catabolism resulting in increased plasma LDL cholesterol 18 - 19 and apo B concentrations. 20 In FH, a genetic defect in the receptor for LDL results in excess accumulation of LDL in plasma, along with LDL-derived cholesterol deposition in atheromas and tendon xanthomas. 1819 The common heterozygous form of FH is characterized by a twofold to threefold elevation in plasma LDL cholesterol and accelerated atherosclerosis.
In the present study, we tested the effects of n-3 and n-6 fatty acid-enriched diets on lipoprotein and apolipoprotein levels in subjects with heterozygous FH. The results indicate that the LDL cholesterol and apo B responses of FH subjects to n-3 and n-6 fatty acids are comparable to those in normal controls but are in marked contrast to the effects previously observed in subjects with FCHL. 14 
Methods
Subjects
Five normolipidemic subjects and five subjects with well-characterized heterozygous FH were studied ( Table 1 ). The five normal subjects included four men and one woman free of known medical problems, taking no medications, and without a known family history of premature coronary artery disease. Three men and two women with FH were recruited from the University Hospital Lipid Clinic. Each met strict diagnostic criteria for this disorder, including first-degree relatives exhibiting hypercholesterolemia without hypertriglyceridemia. Two of the men demonstrated tendon xanthomas, and four subjects had a strong family history of premature cardiovascular disease. The 21-year-old female subject without a family history of early cardiovascular disease had a sister, mother, and maternal grandmother with clearly documented elevations in plasma total and LDL cholesterol. All FH subjects were without cardiovascular disease or other chronic illness at the time of investigation. Lipid-lowering drugs were discontinued at least 6 weeks before initiation of the study. One FH subject received Depakote 1,750 mg/day, Abbott Laboratories, North Chicago, 111., for a seizure disorder, and another continued oral contraceptive medication throughout the study. Female subjects were studied during the same phase of their menstrual cycle for each dietary period to control for the possible effects of variable estrogen and progesterone levels on lipoprotein metabolism. Written informed consent was obtained from all subjects after review of the project by the institution's Human Subject Review Committee.
Dietary Protocol
All subjects consumed diets wholly prepared in the dietary research kitchen of University Hospital Clinical Research Center (CRC). Meals were consumed at the CRC or packaged for consumption at the subject's convenience. Caloric requirements were estimated for each individual, and minor adjustments were made as necessary for weight maintenance. Weights did not vary significantly for any subject throughout the three dietary periods. All subjects were asked to refrain from consuming any nonsupplied foods or beverages during the dietary periods.
Each subject consumed three natural food diets that varied by type and source of fatty acids: butter, n-6 (safflower oil), and n-3 (salmon oil) ( Table 2 ). The caloric distribution for each diet was 34% fat, 18% protein, and 48% carbohydrate. Each diet was maintained for 3 weeks, followed by a minimum of 3 weeks as a washout period before starting the next diet. The order in which subjects received the diets was varied. All subjects were given a standard daily multivitamin, and four subjects received 325 mg ferrous sulfate daily during each of the study diets.
The butter and n-6 (safflower oil) diets contained skinless chicken or turkey breast as the protein source, and butter or safflower oil was added to the food during preparation. During the n-3 diet, canned salmon or turkey breast served as the protein source, and additional salmon oil was given as a separate component of the meal. The subjects received 67 g of salmon or safflower oil and 82.4 g of butter/2,000 kcal. All three diets contained similar amounts of cereal, fruit, and vegetable foods, which contained less than 8% of the dietary fat, and about 40% of the dietary protein. The salmon oil was distilled 21 to remove most of the cholesterol. Since the distillation also removed vitamin E, the salmon oil was fortified with 250 mg a-tocopherol/100 g oil.
Fatty acids and cholesterol in the salmon oil, butter, and safflower oil were analyzed by thin-layer and gas chromatography 22 and were calculated in the other foods 23 -24 (Table 2 ). These foods contained approximately 85% of the total dietary fat.
The butter diet contained 150 mg cholesterol/1,000 kcal, and crystalline cholesterol (Sigma Chemical Co., St. Louis, Mo.) was added to the safflower and salmon oils to match that in the control diet. In addition, the 156 mg/1,000 kcal of plant sterols in the safflower oil diet was matched in the butter and salmon oil diets by solubilizing soy plant sterol mixtures (Heckel Soya Co., Minneapolis, Minn.) in the fats.
Laboratory Procedures
Fasting blood samples were collected into tubes containing 0.1% EDTA three times during the final week of each 3-week diet and analyzed for total plasma cholesterol and triglyceride concentration. In addition, plasma lipoprotein fractions and wholeplasma apolipoproteins were analyzed in two or three of the third-week plasma samples. Enzymatic methods were used for cholesterol and triglyceride quantification of whole plasma and plasma fractions. 25 Density (d) ultracentrifugation of whole plasma (d=1.006 g/ml) was performed at 105,000# for 18 hours to separate VLDL (d< 1.006 g/ml) from intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) (d> 1.006 g/ml) lipoproteins. 26 Density ultracentrifugation was repeated after adjustment of the plasma to d=1.019 g/ml with potassium bromide to separate IDL (d< 1.019 g/ml) from LDL and HDL (d> 1.019 g/ml) lipoproteins. 26 HDL lipoprotein was isolated from the d> 1.019 g/ml fraction using dextran sulfate-magnesium precipitation. 27 LDL cholesterol was calculated as the difference between the d> 1.019 g/ml fraction minus HDL cholesterol. 26 IDL cholesterol was calculated as d> 1.006 g/ml cholesterol minus d> 1.019 g/ml cholesterol. VLDL cholesterol was calculated as the difference between the total plasma cholesterol and the d> 1.006 g/ml fraction. 26 Measured VLDL cholesterol in the d< 1.006 g/ml lipoprotein fraction (results not shown) served as a quality control for calculated VLDL cholesterol. 26 Total plasma cholesterol and triglyceride levels were obtained on all samples, and two or three of the third-week plasma samples were analyzed for VLDL, IDL, LDL, and HDL cholesterol and for apos A-I, 28 A-II, 29 and B 30 by radioimmunoassay. Data are reported as mean of third-week values for each individual during each diet. Plasma fatty acid composition as determined by gas chromatography was obtained at the end of each dietary period. 22 
Statistical Analysis
Results are expressed as mean±SEM. The twotailed paired Student's t test was used to determine statistically significant data. 31 In addition, the nonparametric sign test was used to detect significant differences in plasma HDL cholesterol values.
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Results
Individual lipoprotein and apolipoprotein responses to each diet for both normolipidemic and FH subjects, as well as group means, are given in TablesTABLE 3 ( Figure 1 ) when compared with butter diet values (Table 3 ). There was a significantly greater reduction (/?=0.002) in total cholesterol levels with the salmon oil than the safflower oil diet in FH subjects ( Figure  1 ). These reductions in total cholesterol were primarily due to decreases in plasma LDL cholesterol levels. When compared with butter diet values, plasma LDL cholesterol fell 29±2% (/><0.001) on the safflower oil diet and 31 ±2% (/?<0.001) on the salmon oil diet (Figure 2 ). Additional reductions were noted in IDL cholesterol, which fell 46 ±9% and 65 ±10% (both p<0.01) during the safflower oil and salmon oil diets, respectively. Plasma VLDL cholesterol did not significantly change during the safflower oil diet but was reduced 71±4% (/><0.001) during the salmon oil diet when compared with butter diet values (p<0.001 for the difference between salmon oil and safflower oil diet changes; Figure 2 ).
In normal subjects, similar reductions in total plasma cholesterol were noted with the safflower oil (-25±2%) and salmon oil (-28±2%; bothp<0.001) diets when compared with the butter-based diet (Table 3, Figure 1 ). Likewise, plasma LDL cholesterol values in the normal controls decreased 30±3% on the safflower oil diet and 31±3% (bothp<0.001) on the salmon oil diet (Figure 2 ). Plasma VLDL cholesterol concentrations in normal subjects did not significantly change from those on the butter diet during the safflower oil (-6±26%,/?=NS) or salmon oil diet (-44±24%, p=NS); however, the percent change during the salmon oil diet was significantly different than that observed with the safflower oil diet (Figure 2) .
In FH subjects, total plasma triglyceride levels did not significantly change from butter diet values during the safflower oil diet (-12±6%,/?=NS) but fell 44±5% (/?<0.001) during the salmon oil diet (Table 3, Figure 1 ). The reduction in plasma triglyceride was significantly greater with the salmon oil diet than the safflower oil diet in FH subjects (p=0.016, Figure 1) . No significant reductions were noted in normals from butter diet total plasma triglyceride concentrations on the safflower oil diet (-11 ±14%, />=NS), but salmon oil diet triglyceride levels decreased 32±9% (p=0.03). FH plasma HDL cholesterol concentrations (Table 3) did not significantly change during the safflower oil diet (-5±4%) when compared with the butter diet but decreased 12±2% (p=0.002, Figure  2 ) during the salmon oil diet. In normal subjects, plasma HDL cholesterol levels decreased 19±5% (/?=0.02) during the salmon oil and 10±l% (/?=0.003) with the safHower oil diets when compared with butter diet levels.
Plasma apo A-I (Table 4 , Figure 3 ) did not change from butter diet values during the salmon oil (-5±5%,/?=NS) and safflower oil (8±6%,/?=NS) diets in FH subjects; however, significant reductions were noted in normal subjects during the safflower oil ( -7 ± 1 % , p=0.007) and salmon oil (-16±2%, p<0.001) diets. The response of apo A-I to the salmon oil and safflower oil diets was significantly different for both FH and normal subjects (both /?<0.05, Figure 3 ). Likewise, plasma apo A-II concentrations were unchanged from butter diet values in FH subjects during salmon oil (-11 ±6%,/?=NS) and safflower oil (6±9%,/?=NS) diets and in normal subjects consuming a safflower oil diet (2±4%, />=NS) but fell 8±2% (/7=0.02) in normal subjects during the salmon oil diet. The response of apo A-II to the salmon oil diet was significantly different from that of the safflower oil diet in normal subjects (p=0.03, Figure 3 ).
Plasma apo B levels (Table 4, Figure 3 ) decreased from butter diet values in FH subjects 27 ±4% (p=0.002) on the safflower oil diet and 28±1% (p<0.001) with the salmon oil diet, while normolipidemic apo B levels fell 25 ±4% (p=0.002) and 18±5% (p=0.03) during the safflower oil and salmon oil diets, respectively.
Plasma eicosapentaenoic acid levels increased from a mean of 1% of total fatty acids during the butter and safflower oil diets to 17% in FH and 16% in normal subjects (both p< 0.001) on the salmon oil diet. Plasma docosahexaenoic acid levels increased from 2% of total fatty acids in FH and normal subjects on the butter and safflower oil diets to 8% (p<0.005) in FH and 10% (p<0.05) in normal subjects during the salmon oil diet. Linoleic acid levels were 30% and 15% of total fatty acids during the butter and salmon oil diets, respectively, but increased to 46% (p<0.001) with the safflower oil diet in FH subjects. Normal subject linoleic acid levels were 26% and 12% of total fatty acids during the butter and salmon oil diets, respectively, and increased to 47% (p<0.001) with the safflower oil diet.
Discussion
Results in this study demonstrate a striking reduction in total and LDL cholesterol as well as in apo B levels in subjects with FH consuming n-3 and n-6 14 demonstrated increases in plasma LDL apo B levels in three of four men with FCHL consuming a similar salmon oil-rich diet when compared with a butter-based diet.
9 Similar elevations in LDL apo B concentrations were noted by Sullivan et al 13 in 23 hypertriglyceridemic subjects treated with 15 g/day of a fish oil concentrate (Max-EPA) for at least 4 weeks.
Mechanisms for the reduction in plasma LDL cholesterol levels in these normal and FH subjects are not fully elucidated, but they likely include a decrease in VLDL cholesterol synthesis as documented by Nestel et al 12 in five normal and two hypertriglyceridemic subjects consuming metabolic diets supplemented with MaxEPA. Furthermore, reductions in LDL cholesterol synthesis but not degradation have been described by Illingworth et al 33 in seven normal subjects consuming an n-3-enriched diet. The most likely mechanism for a decrease in plasma LDL cholesterol concentrations in FH and normal subjects is via a reduction in VLDL cholesterol synthesis, which would then limit the amount of cholesterol converted to LDL cholesterol. To date, no studies have demonstrated an effect of n-3 fatty acids on LDL receptor activity in humans, but normolipidemic rats fed an n-3-enriched diet have been shown to increase hepatic clearance of LDL cholesterol via an increase in LDL receptor activity. 34 Therefore, it is possible that n-3 fatty acids may also upregulate LDL receptor activity in humans with FH and promote clearance of LDL cholesterol from the plasma.
HDL cholesterol levels were reduced during salmon oil feeding. However, in FH subjects, apo A-I and A-II concentrations were not significantly altered with the safflower oil or salmon oil diet. In normal subjects, apo A-I levels fell with both diets, but apo A-II concentrations were only reduced with the salmon oil diet. The mechanism of this effect and its potential significance remain to be determined.
Salmon served as the source of n-3 fatty acids in this dietary study. Further investigation will be necessary to determine the effects of other n-3 sources on LDL cholesterol levels in FH subjects. Furthermore, large quantities of n-3 fatty acids were ingested to test the maximal effect of n-3 fatty acids because a preliminary study suggested a dose-dependent effect of n-3 fatty acids on plasma lipoproteins. 35 Therefore, smaller amounts of n-3 fatty acids that would be realistic for humans to consume on a daily basis would be unlikely to improve lipoprotein levels to a similar extent as in these subjects. Salmon oil also contains a relatively large amount of monounsaturated fatty acids, which may reduce lipoprotein concentrations; monounsaturated-rich oleic acid diets reduce LDL cholesterol levels in normal and hypertriglyceridemic subjects when substituted for saturated fat. 32 In summary, diets enriched with n-6 and n-3 polyunsaturated fatty acids reduced plasma total, VLDL, and LDL cholesterol as well as triglyceride and apo B levels to a similar extent in FH subjects and normal controls when compared with a diet rich in saturated fatty acids. Thus, dietary n-3 and n-6 fatty acids, when substituted for saturated fat, may be beneficial in lowering elevated LDL levels in patients with heterozygous FH. While dietary alteration will not reduce LDL cholesterol and apo B concentrations to "normal" levels in most individuals with this genetic disorder, dietary alterations that exchange saturated fatty acids for both types of polyunsaturated fatty acids should play an important role in the total treatment plan aimed at reducing the levels of atherogenic lipoproteins in patients with heterozygous FH.
